Insulet (NASDAQ:PODD) Shares Unloaded Sen. Tina Smith

Senator Tina Smith (Democratic-Minnesota) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in Insulet stock on April 29th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

Insulet Price Performance

NASDAQ:PODD traded up $5.31 during mid-day trading on Tuesday, reaching $159.48. 559,349 shares of the stock were exchanged, compared to its average volume of 1,107,011. The business has a fifty day moving average price of $207.40 and a 200 day moving average price of $261.40. The firm has a market capitalization of $11.05 billion, a PE ratio of 37.04, a PEG ratio of 1.25 and a beta of 1.20. Insulet Corporation has a 1-year low of $148.30 and a 1-year high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts expect that Insulet Corporation will post 6.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet in the fourth quarter worth about $26,000. Elyxium Wealth LLC bought a new stake in shares of Insulet during the 4th quarter worth about $28,000. DV Equities LLC acquired a new position in shares of Insulet during the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the 4th quarter valued at about $29,000.

Insider Activity at Insulet

In related news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. Wells Fargo & Company dropped their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Citigroup dropped their price target on Insulet from $230.00 to $175.00 in a research note on Thursday, May 7th. Stifel Nicolaus dropped their price target on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. BTIG Research dropped their price target on Insulet from $320.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Nineteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus price target of $257.09.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.